Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Skyrizi’s New IV Form Now Available for Crohn’s Disease
AbbVie launched a new 600 mg intravenous drip infusion version of its IL-23 inhibitor Skyrizi (risankizumab) in Japan on January 13 for the treatment of moderately to severely active Crohn’s disease inadequately controlled with existing therapies.The new formulation was approved…
To read the full story
Related Article
- AbbVie Rolls Out Skyrizi Auto-Doser in Japan
February 14, 2023
BUSINESS
- Daiichi-AZ, Summit Team Up on Datroway Combo in Multiple Cancers
October 5, 2026
- Stargardt Diagnosis System Needs Bolstering as Treatment Nears: Expert
October 5, 2026
- Maruho Expands Rapifort Deal with Orient EuroPharma to ASEAN
October 5, 2026
- CellFiber Opens US Base to Drive Adoption of Cell Culture Technology
October 5, 2026
- JCR Licenses Izcargo Rights to Italfarmaco in US, Europe, Latin America
October 5, 2026
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
The development of Boehringer Ingelheim’s survodutide is gathering pace, putting the GLP-1/glucagon receptor agonist in contention to become the next…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…